[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603012":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":36,"collaborators":7,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Hacettepe University","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"İzgi BAYRAKTAR, PhD (c)- Lecturer","CONTACT","+905342996472","izgibayraktar@gmail.com",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Aygin Ekincioglu, Prof.Dr. -Head of department","+90 532 355 07 46","aygin@hacettepe.edu.tr",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":7,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Hacettepe University Faculty of Pharmacy, Department of Clinical Pharmacy","RECRUITING","Ankara","Altındağ","06100","Turkey (Türkiye)",{"type":27,"coordinates":28},"Point",[29,30],32.85427,39.91987,{"lat":30,"lon":29},[33],{"name":34,"role":11,"phone":35,"phoneExt":7,"email":17},"Aygin Ekincioglu, Professor","(0 312) 305 20 43",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","İzgi Bayraktar","PhD candidate","100603012",false,"NCT07130981","Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients","Evaluation of Body Composition, Psychosocial Factors, and Drug-Related Problems in Relation to Clinical Progression in Cancer Patients Receiving Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Aged 18 years or older\n* Having undergone a CT scan (at the L3 level) prior to treatment\n* No severe mental disorder and able to communicate effectively\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Did not provide written informed consent\n* Patients deemed unsuitable by the physician","ALL","18 Years",{"count":49,"type":50},200,"ESTIMATED","OBSERVATIONAL","Evaluation of the effects of body composition, psychosocial factors, and drug-related problems on clinical progression (such as toxicity, treatment response, and quality of life) in cancer patients treated with immune checkpoint inhibitors",[54,55,56,57],"Cancer","Psychosocial Functioning","Treatment Side Effects","Cachexia","2025-08-19",{"date":60,"type":61},"2025-08-24","ACTUAL",{"date":63,"type":50},"2025-09-01",{"date":65,"type":50},"2026-01-01",{"name":5,"class":6},1]